We are live on
!
Find out more
O
Ossiam Portfolio holdings
AUM
$5.69B
1-Year Est. Return
30.95%
This Fund
S&P 500
This Quarter
Est. Return
+8.43%
1 Year Est. Return
+30.95%
3 Year Est. Return
+104.81%
5 Year Est. Return
+127.55%
10 Year Est. Return
–
AUM
$1.31B
AUM Growth
-$122M
(-8.5%)
Cap. Flow
-$203M
Cap. Flow
% of AUM
-15.51%
Top 10 Holdings %
Top 10 Hldgs %
37.2%
Holding
529
New
58
Increased
189
Reduced
228
Closed
54
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Johnson & Johnson
JNJ
|
+$55.6M |
| 2 |
Mastercard
MA
|
+$42M |
| 3 |
Procter & Gamble
PG
|
+$37.7M |
| 4 |
AT&T
T
|
+$36.5M |
| 5 |
Amgen
AMGN
|
+$28.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$71.9M |
| 2 |
Wells Fargo
WFC
|
+$50.4M |
| 3 |
Linde
LIN
|
+$39.2M |
| 4 |
Walt Disney
DIS
|
+$39M |
| 5 |
CVS Health
CVS
|
+$32.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 23.16% |
| 2 | Communication Services | 14.07% |
| 3 | Healthcare | 13.47% |
| 4 | Financials | 12.21% |
| 5 | Consumer Staples | 10.8% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
476
Alnylam Pharmaceuticals
ALNY
$36.3B
| – | – |
-572
| Closed | -$46K |
|
477
Baxter International
BAX
$11.6B
| – | – |
-25,615
| Closed | -$2.24M |
|
478
Best Buy
BBY
$18B
| – | – |
-717
| Closed | -$49K |
|
|
BLD
479
DELISTED
TopBuild
BLD
| – | – |
-7,356
| Closed | -$709K |
|
480
Conagra Brands
CAG
$7.07B
| – | – |
-11,371
| Closed | -$349K |
|
481
Cardinal Health
CAH
$53.4B
| – | – |
-7,877
| Closed | -$372K |
|
482
Centene
CNC
$31.3B
| – | – |
-14,404
| Closed | -$623K |
|
483
Cencora
COR
$60.3B
| – | – |
-633
| Closed | -$52K |
|
484
Carlisle Companies
CSL
$13.6B
| – | – |
-3,974
| Closed | -$578K |
|
485
Dell
DELL
$283B
| – | – |
-2,940
| Closed | -$77K |
|
486
Erie Indemnity
ERIE
$11.7B
| – | – |
-975
| Closed | -$181K |
|
487
FedEx
FDX
$74.5B
| – | – |
-606
| Closed | -$88K |
|
488
F5
FFIV
$22.1B
| – | – |
-3,470
| Closed | -$487K |
|
489
Global Payments
GPN
$22.1B
| – | – |
-160
| Closed | -$25K |
|
|
HBI
490
DELISTED
Hanesbrands
HBI
| – | – |
-3,250
| Closed | -$50K |
|
|
HES
491
DELISTED
Hess
HES
| $0 | ﹤0.01% |
5
-123
| -96% | -$8.05K |
|
492
Honeywell
HON
$77.1B
| – | – |
-16,489
| Closed | -$2.63M |
|
493
Humana
HUM
$46.7B
| – | – |
-907
| Closed | -$232K |
|
494
iShares MSCI India ETF
INDA
$6.71B
| – | – |
-575,558
| Closed | -$19.2M |
|
495
IQVIA
IQV
$34.7B
| – | – |
-1,947
| Closed | -$291K |
|
496
Jazz Pharmaceuticals
JAZZ
$15.9B
| – | – |
-106
| Closed | -$14K |
|
497
iShares MSCI Saudi Arabia ETF
KSA
$647M
| – | – |
-805,000
| Closed | -$24.4M |
|
498
Lennox International
LII
$18.8B
| – | – |
-1,835
| Closed | -$446K |
|
499
LKQ Corp
LKQ
$6.58B
| – | – |
-9,192
| Closed | -$289K |
|
500
Microchip Technology
MCHP
$42.8B
| – | – |
-6,292
| Closed | -$292K |
|
Similar funds
AIM
ACM
PI
TSW
VH
DCP
F
RMDI
Ossiam's Q4 2019 Portfolio in Review
As of Q4 2019, Ossiam held 529 positions worth $1.31B, down 8.5% from $1.43B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
Ossiam withdrew a net $203M in Q4 2019, closing 54 positions and reducing 228 holdings. Its most notable exit was Celgene Corp, an estimated $71.9M position sold in full.
By sector, the portfolio is most concentrated in Technology at 23% of assets, up from 20% a quarter earlier, followed by Communication Services and Healthcare.
Against the trend, Ossiam opened a new position in Alcon worth $14.8M.
- Ossiam's largest Q4 2019 buy was Alcon: 260,957 shares worth $14.8M.
- Ossiam added most to Johnson & Johnson in Q4 2019, an estimated $55.6M increase.
- Ossiam's biggest Q4 2019 reduction was Linde, cutting an estimated $39.2M.
- Ossiam fully exited Celgene Corp in Q4 2019, selling an estimated $71.9M.
- Ossiam's ten largest holdings make up 37% of its $1.31B portfolio in Q4 2019.
- Ossiam opened 58 new positions and closed 54 in Q4 2019.
- Ossiam's portfolio value fell 8.5% quarter-over-quarter to $1.31B.
Based on Ossiam's 13F filing for Q4 2019, filed 14 Feb 2020.